Johnson & Johnson
JNJ
Market Cap$360.81B
Close$
Earnings Call Q4 2023
January 23, 2024 - AI Summary
Johnson & Johnson reported strong financial results for Q4 2023, with worldwide sales of $21.4 billion, representing a 7.2% increase compared to the previous year.
The company's Innovative Medicine business delivered above-market operational sales growth of 9.5%, excluding the COVID-19 vaccine, driven by key brands and new product launches.
MedTech also performed well, with operational sales growth of 9.1%, reaching over $30 billion in sales for the first time.
Exclusive for Stockcircle Pro members
Sign up
$147.64
1.5% downside
Current Fair Value
1.5% downsideOvervalued by 1.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $360.81 Billion |
|---|---|
| Enterprise Value | $368.22 Billion |
| Dividend Yield | $4.7059 (3.14%) |
| Earnings per Share | $13.73 |
| Beta | 0.24 |
| Outstanding Shares | 2,406,679,183 |
| Avg 30 Day Volume | 8,590,624 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 10.26 |
|---|---|
| PEG | -0.21 |
| Price to Sales | 4.54 |
| Price to Book Ratio | 5.17 |
| Enterprise Value to Revenue | 4.5 |
| Enterprise Value to EBIT | 17.18 |
| Enterprise Value to Net Income | 9 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.48 |
Revenue Sources
No data
ESG Score
No data
About Johnson & Johnson
CEO: Alex Gorsky At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today...